Literature DB >> 9296352

Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes.

L A Trepanier1, K Ray, N J Winand, S P Spielberg, A E Cribb.   

Abstract

The purpose of this study was to determine the molecular basis in the dog for an unusual and absolute deficiency in the activity of cytosolic N-acetyltransferase (NAT), an enzyme important for the metabolism of arylamine and hydrazine compounds. NAT activity towards two NAT substrates, p-aminobenzoic acid and sulfamethazine, was undetectable in dog liver cytosol, despite substrate concentrations ranging from 10 microM to 4 mM and a wide range of incubation times. Similarly, no protein immunoreactive to NAT antibody was evident on western blot analysis of canine liver cytosol. Southern blot analysis of genomic DNA from a total of twenty-five purebred and mixed bred dogs, and eight wild canids, probed with a full-length human NAT2 cDNA, suggested an absence of NAT sequences in all canids. Polymerase chain reaction amplification of genomic DNA using degenerate primers designed to mammalian NAT1 and NAT2 consensus sequences generated products of the expected size in human, mouse, rabbit, and cat DNA, but no NAT products in any dog or wild canids. These results support the conclusion that cytosolic NAT deficiency in the domestic dog is due to a complete absence of NAT genes, and that this defect is shared by other canids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9296352     DOI: 10.1016/s0006-2952(97)00140-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

2.  Comparison of hydrolytic and conjugative biotransformation pathways in horse, cattle, pig, broiler chick, rabbit and rat liver subcellullar fractions.

Authors:  F Gusson; M Carletti; A Giuliano Albo; M Dacasto; C Nebbia
Journal:  Vet Res Commun       Date:  2006-04       Impact factor: 2.459

3.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

4.  Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons.

Authors:  David J Wilkinson; Rosalind L Southall; Mingguang Li; Lisa M Wright; Lindsay J Corfield; Thomas A Heeley; Benjamin Bratby; Ranbir Mannu; Sarah L Johnson; Victoria Shaw; Holly L Friett; Louise A Blakeburn; John S Kendrick; Michael B Otteneder
Journal:  AAPS J       Date:  2017-05-04       Impact factor: 4.009

Review 5.  Species differences in tumour responses to cancer chemotherapy.

Authors:  Jessica Lawrence; David Cameron; David Argyle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

6.  Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations In Vitro.

Authors:  Joseph M Covey; Joel M Reid; Sarah A Buhrow; Mary Kuffel; Chad Walden; Holger Behrsing; Matthew M Ames
Journal:  J Drug Metab Toxicol       Date:  2016-05-08

Review 7.  Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model.

Authors:  Steven Fleischer; Michele Sharkey; Katrina Mealey; Elaine A Ostrander; Marilyn Martinez
Journal:  AAPS J       Date:  2008-02-15       Impact factor: 4.009

Review 8.  Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-09       Impact factor: 2.093

9.  Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Lawrence W Anderson; Raymond W Klecker; Alice Chen; Anthony J Murgo; James H Doroshow; Jerry M Collins
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-03       Impact factor: 3.333

10.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.